DR info

Clinical trials : 9 / Drugs : 10 - (DrugBank : 5) / Drug target genes : 4 - Drug target pathways : 7

Drugs and their primary sponsors and trial info

Acylated and unacylated ghrelin dosages
   University Hospital, Toulouse
      2021   -   NCT04768803   -
DTR Melatonin (NIH CC PDS)
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1   NCT00506259   United States;
Enviro-light artificial light box
   Oregon Health and Science University
      1998   -   NCT00691574   United States;
Hourly dosing of the nychtemeral secretion of melatonin
   Hôpital le Vinatier
      2018   -   NCT03492970   France;
Melatonin
   Oregon Health and Science University
      1998   -   NCT00691574   United States;
Melatonin CR
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1   NCT00506259   United States;
Phototherapy (Bright Light)
   National Human Genome Research Institute (NHGRI)
      2007   Phase 1   NCT00506259   United States;
RM-493
   Rhythm Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2017-000387-14-GR   Canada;France;Germany;Greece;Israel;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000387-14-GB   Canada;France;Germany;Greece;Israel;Netherlands;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2017-000387-14-FR   Australia;Canada;France;Germany;Greece;Ireland;Israel;Netherlands;Portugal;Spain;Turkey;United Kingdom;United States;
Setmelanotide
   Rhythm Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2017-000387-14-GR   Canada;France;Germany;Greece;Israel;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 2/Phase 3   NCT03013543   Canada;France;Germany;Greece;Israel;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000387-14-GB   Canada;France;Germany;Greece;Israel;Netherlands;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2017-000387-14-FR   Australia;Canada;France;Germany;Greece;Ireland;Israel;Netherlands;Portugal;Spain;Turkey;United Kingdom;United States;
Tasimelteon
   Vanda Pharmaceuticals
      2016   Phase 1   NCT02776215   United States;
      2015   Phase 2/Phase 3   NCT02231008   United States;